CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
Busulfex, Fludarabine, ALemtuzumabdrug
Likely dose
Busulfex, Fludarabine, ALemtuzumab 3.2 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00582894
NCT00582894N/ACompleted
CompareCT.gov

Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases

University of Oklahoma·interventional·Posted Dec 28, 2007·Updated Apr 22, 2011

In Brief

A clinical study evaluating Busulfex, Fludarabine, ALemtuzumab for Hematological Neoplasms and Hematopoietic Stem Cell Transplantation. Completed, enrolled 17 participants across 1 site.

Detailed Summary

To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematological Neoplasms, Hematopoietic Stem Cell Transplantation
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 28, 2007
Enrollment StartFeb 1, 2005
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 18.5 years ago

Interventions

Busulfex, Fludarabine, ALemtuzumabdrug

Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1